Corcept Therapeutics Incorporated (CORT)

Corcept Therapeutics Incorporated (CORT) is a healthcare company (biotechnology) based in the United States. The share price is $70.82, up 2.31% on the day, which values the company at $7.75B. Price as of 17 Nov 2026, 17:14 UTC, from Yahoo Finance.

Key facts

Share price
$70.82+2.31% today
Market value
$7.75B
P/E ratio
53.2×last 12 months
Forward P/E
14.2×
Funk Score
59/100
Against its own history
Well above its usual priceusual price $35.91
200-week average
$50.7140% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Corcept Therapeutics Incorporated in more detail

CORT trades at 53.2× its last twelve months' earnings, 14.2× next year's expected earnings, 8.0× sales. Measured against its own history, the price is 97% above what its usual multiples would imply ($35.91) — well above its usual price. It sits 40% above its 200-week average of $50.71.

Over the last five fiscal years Corcept Therapeutics Incorporated has compounded revenue 16.6% a year, earnings per share -0.7% a year, free cash flow -1.2% a year. Its Funk Score is 59 out of 100 (financial strength 8.9, profitability 5.3, growth 6.0, value 3.3, each out of 10).

In its favour: Altman Z in the safe zone; Five straight years of revenue growth. Worth checking: Gross margin is shrinking.

1 of the superinvestors tracked here hold CORT, including Jim Simons (1938–2024) (0.8% of the portfolio).

Superinvestors holding CORT

1 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:CORT vs HQY (Corcept Therapeutics Incorporated vs HealthEquity)CORT vs TXG (Corcept Therapeutics Incorporated vs 10x Genomics)CORT vs RYTM (Corcept Therapeutics Incorporated vs Rhythm Pharmaceuticals)CORT vs ALKS (Corcept Therapeutics Incorporated vs Alkermes)CORT vs PACS (Corcept Therapeutics Incorporated vs PACS Group)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

Corcept Therapeutics Incorporated (CORT): questions and answers

What is CORT's P/E ratio?

Corcept Therapeutics Incorporated trades at 53.2× its last twelve months' earnings and 14.2× next year's expected earnings. At its fiscal year-ends over the past 10 years the P/E ranged from 15.7× to 103.7×, with a median of 27.1×.

What is CORT's PEG ratio?

Corcept Therapeutics Incorporated's PEG ratio is 0.81 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is Corcept Therapeutics Incorporated's market cap?

Corcept Therapeutics Incorporated is valued at $7.75B at a share price of $70.82.

Is CORT overvalued or undervalued?

Against its own history, CORT is well above its usual price: the price is 97% above the $35.91 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is CORT above its 200-week moving average?

Yes. CORT is 39.7% above its 200-week average of $50.71. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Corcept Therapeutics Incorporated growing?

Over the last five fiscal years Corcept Therapeutics Incorporated's revenue grew 16.6% a year and its earnings per share -0.7% a year; over ten years revenue grew 31.2% a year.

Cite this page

Funkfolio, “Corcept Therapeutics Incorporated (CORT) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/CORT

Underlying data: Yahoo Finance; company filings with the SEC.